Figure 5. Therapeutic TriVax results in increased survival.

(A), B6 mice (8 per group) received 3 different doses of B16F10 cells i.v. (as indicated) and 3 days later the mice were immunized with either Trp2_180–188-TriVax, Ova_55–63-TriVax or left unvaccinated (No Vax). P values were determined by log-rank tests. (B), At the termination of the experiment presented in (A), survivor mice were pooled, randomized and received s.c. tumor challenge with either B16F10 or B16F10-kb⁻ cells (5 × 10⁵ cell/mouse). Naï ve, unvaccinated mice inoculated with the same number of tumore cells were included as control. Tumore sizes were determined in individual mice by measurements of 2 opposing diameters and are presented as tumore areas in mm². Each data point corresponds to the means and SD for each group of mice (5 per group). P value was calculated using two-ways ANOVA test.